Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 41

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 41
---
 have an adverse effect on the market price of our common stock and make it more difficult to effect a business combination.

We will be issuing the Warrants to purchase shares
of common stock as part of this offering. To the extent we issue shares of common stock to effect a future business combination, the potential
for the issuance of a substantial number of additional shares upon exercise of the Warrants, or the potential for us to be required to
pay to the Warrant holders an amount in cash equal to the Black-Scholes Value (as defined in the Warrants), could make us a less attractive
acquisition vehicle in the eyes of a target business. Such Warrants, when exercised, will increase the number of issued and outstanding
shares of common stock and reduce the value of the shares issued to complete the business combination. Accordingly, the Warrants may make
it more difficult to effectuate a business combination or increase the cost of acquiring a target business. Additionally, the sale, or
even the possibility of a sale, of the shares of common stock underlying the Warrants could have an adverse effect on the market price
for our securities or on our ability to obtain future financing. If and to the extent the Warrants are exercised, you may experience dilution
to your holdings.

We will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.

Each Pre-Funded Warrant will be exercisable by
means of payment of the nominal cash purchase price upon exercise. Accordingly, we will not receive any or any meaningful additional funds
upon the exercise of the Pre-Funded Warrants.

<div align='center'>20</div>

The Warrants are not exercisable until the Warrant Stockholder Approval; provided, however, that if the Pricing Conditions are met, the Common Warrants will be exercisable upon issuance.

The Warrants will have an assumed exercise price
of $ per share and will be exercisable beginning on the effective
date of the Warrant Stockholder Approval; provided, however, that if the Pricing Conditions are met, the Warrants will be exercisable
upon issuance the Initial Exercise Date. The Series A-1 Warrants will expire on the anniversary
of the Warrant Stockholder Approval or Initial Exercise Date, as applicable, and the Series A-2 Warrants will expire on the anniversary
of the Warrant Stockholder Approval or Initial Exercise Date, as applicable.

While we intend to promptly seek Warrant Stockholder
Approval, if needed, there is